Substantive Updates Part One: What Women Leaders in Life Sciences Law Must Know About Products Liability, Mass Torts, and “Bet-the-Company” Litigation

July 28, 2016 11:15am

Brandee J. Kowalzyk
Nelson Mullins Riley & Scarborough LLP (Atlanta, GA)

Colleen M. Hennessey
Peabody & Arnold LLP (Boston, MA)

Melissa A. Geist
Partner and Co-Chair, Life Sciences Health Industry Group
Reed Smith LLP (Princeton, NJ)

Candace Camarata
Assistant General Counsel
C.R. Bard, Inc. (Murray Hill, NJ)

To truly be industry leaders, women need to stay on the competitive edge by having the big picture view of the most cutting-edge legal challenges in the fast-moving life sciences space. In this substantive session and the ones that follow, leading attorneys and government representatives will give you a rundown on the most pressing developments affecting the future of life sciences companies.

  • Updates on key mass torts, bellwethers, MDLs, and state-coordinated proceedings from around the country
  • Tales from the trenches of products liability litigation: what are the new theories of liability plaintiffs’ attorneys are using against pharmaceutical and medical device manufacturers?
  • Recent developments to watch including discovery torts and document preservation after Federal Rule changes and billion dollar Actos litigation; generic and medical device preemption; third party funding
  • What’s next for products liability: 3D printing, biosimilars, personalized medicine and more